We are live on
!
Find out more
Axsome Therapeutics
AXSM
AXSM
30 hedge funds and large institutions have $33.3M invested in Axsome Therapeutics in 2017 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
1.67% less ownership
Funds ownership: 27.12% → 25.45% (-1.7%)
6% less capital invested
Capital invested by funds: $35.3M → $33.3M (-$1.97M)
14% less funds holding
Funds holding: 35 → 30 (-5)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
50% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 10
Holders
30
Holders Change
-5
Holders Change %
-14.29%
% of All Funds
0.75%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
6
Reduced
8
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$769K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$268K |
| 3 |
Squarepoint
New York
|
+$180K |
| 4 |
JP Morgan Chase
New York
|
+$125K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$115K |
Top Sellers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.22M |
| 2 |
SCM
Sio Capital Management
New York
|
-$880K |
| 3 |
Goldman Sachs
New York
|
-$372K |
| 4 |
ECM
Element Capital Management
New York
|
-$338K |
| 5 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$269K |
